Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.49 |
| ▸ | CCR9 | P51686 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265567 | 0.85 | PTGS2 (0.68) | PTGS2PTGS1KMT2A | |
| SCHEMBL5546174 | 0.78 | CCR9 (0.44) | PTGS2PTGS1CCR9KMT2A | |
| SCHEMBL8192267 | 0.77 | ENPP3 (0.42) | PTGS2PTGS1KMT2A | |
| SCHEMBL9434736 | 0.74 | NPC1 (0.39) | PTGS2PTGS1KMT2A | |
| SCHEMBL21051602 | 0.74 | NPC1 (0.40) | PTGS2PTGS1CCR9KMT2A | |
| SCHEMBL1617773 | 0.74 | ACHE (0.43) | PTGS2PTGS1KMT2A | |
| SCHEMBL5545503 | 0.74 | PTGS2 (0.54) | PTGS2PTGS1CCR9KMT2A | |
| SCHEMBL342242 | 0.74 | MAPK13 (0.58) | PTGS2KMT2A | |
| SCHEMBL344928 | 0.72 | IMPDH2 (0.46) | PTGS2PTGS1KMT2ACA12CA1 | |
| SCHEMBL8192595 | 0.70 | LMNA (0.43) | PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170369483-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| EP-1798223-B2 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8211896-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| EP-1798223-B1 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110021523-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1798223-A2 | Aryl sulfonamides | ChemoCentryx Inc (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6939885-B2 | Aryl sulfonamides | CHEMOCENTRYX (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1562940-A2 | ARYL SULFONAMIDES | ChemoCentryx Inc (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050165067-A1 | Aryl sulfonamides | CHEMOCENTRYX | 2005-07-28 | — | — | US | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20170369483-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20110021523-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20050165067-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | PTGS2 1124/4885PTGS1 1214/4885CCR9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.